BioCentury
ARTICLE | Company News

Eisai sales and marketing update

April 8, 2013 7:00 AM UTC

Eisai launched NerBloc botulinum toxin type B intramuscular injection 2,500 unit in Japan to treat cervical dystonia. Each vial has a National Health Insurance (NHI) list price of ¥28,902 ($307). In 2000, Eisai received Japanese rights to the product from Elan Corp. plc (NYSE:ELN, Dublin, Ireland). In 2007, Solstice Neurosciences Inc. (Malvern, Pa.) granted Eisai exclusive rights to commercialize the product in the 27 EU member countries, Norway, Iceland, Liechtenstein, Monaco, Switzerland, Croatia, Turkey and Russia. Solstice bought Elan's NeuroBloc assets in 2004. The product, which is known as NeuroBloc in Europe and Myobloc outside of Europe, is approved in the U.S., Canada and Europe to treat cervical dystonia pain (see BioCentury, Oct. 16, 2000 & May 21, 2007).

Separately, Eisai launched Inovelon rufinamide oral suspension in France for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients four years of age and older. Eisai declined to disclose the price. Eisai markets the triazole derivative in the U.S. as Banzel and in the EU as Inovelon. Rufinamide is also approved for the indication in Switzerland and Canada. ...